Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olysio

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.

Remicade safe from biosimilar competition this year, says J&J

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

J&J's share buyback 'doesn't prevent acquisitions'

J&J's share buyback 'doesn't prevent acquisitions' disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products. ... Olysio continued its slide in the face of competition from new HCV drugs from Gilead and AbbVie, with sales dropping

Taking a strategic approach

Taking a strategic approach Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

First-ever World Hepatitis Summit calls for national programmes

First-ever World Hepatitis Summit calls for national programmes Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two

1 2 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics